Millennium Management’s Indaptus Therapeutics INDP Stock Holding History

Millennium Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,359	Closed	-$217K	–	7164
2021 Q4	$217K	Buy	+1,359	New	+$252K	﹤0.01%	5844
2021 Q1	–	Sell	-419	Closed	-$162K	–	6201
2020 Q4	$162K	Buy	+419	New	+$183K	﹤0.01%	4917
2019 Q3	–	Sell	-18	Closed	-$174K	–	4354
2019 Q2	$174K	Buy	18 +13	+260%	+$164K	﹤0.01%	3792
2019 Q1	$80K	Buy	+5	New	+$87.6K	﹤0.01%	3873
2018 Q4	–	Sell	-21	Closed	-$262K	–	3941
2018 Q3	$262K	Sell	21 -10	-32%	-$95K	﹤0.01%	3541
2018 Q2	$308K	Buy	+31	New	+$344K	﹤0.01%	3378
2018 Q1	–	Sell	-121	Closed	-$1.39M	–	3849
2017 Q4	$1.39M	Buy	+121	New	+$1.87M	﹤0.01%	2501

Other funds holding INDP

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $1.92B AUM 23.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's INDP Position: Q1 2022 in Review

Millennium Management sold out of Indaptus Therapeutics (INDP) in Q1 2022, closing a stake of 1,359 shares — an estimated $217K sold.

Millennium Management first reported a position in INDP in Q4 2017 and held it in 7 quarters. The position peaked at $1.39M in Q4 2017. 15 funds tracked by Wall St. Rank hold INDP as of Q1 2022.

Millennium Management reported no remaining Indaptus Therapeutics position as of Q1 2022 after selling out during the quarter.
Millennium Management sold 1,359 Indaptus Therapeutics shares in Q1 2022, an estimated $217K.
Millennium Management first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 7 quarters.
Millennium Management's Indaptus Therapeutics position peaked at $1.39M in Q4 2017.
15 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.